Shruti Bhatt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3649047/publications.pdf

Version: 2024-02-01

38	936	567281 15	677142 22
papers	citations	h-index	g-index

39	39	39	2005
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia, 2022, 36, 1088-1101.	7.2	6
2	Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models. STAR Protocols, 2021, 2, 100461.	1.2	1
3	Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to reâ€induction chemotherapy. American Journal of Hematology, 2020, 95, 245-250.	4.1	13
4	Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell, 2020, 38, 872-890.e6.	16.8	80
5	Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM). Blood, 2020, 136, 22-23.	1.4	0
6	Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood, 2019, 134, 160-170.	1.4	41
7	Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia. Blood, 2019, 134, 2551-2551.	1.4	0
8	Enhancer Rewiring Dependent Switch from BCL2 to MCL1 Dependency Predicts NOTCH1 Inhibition Response in T-ALL. Blood, 2019, 134, 3948-3948.	1.4	0
9	Abstract 2990: Individualized functional approach to tailoring acute myeloid leukemia therapy. , 2019, , .		0
10	PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood, 2018, 132, 1095-1105.	1.4	160
11	Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine, 2018, 10, .	12.4	61
12	Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia. Blood, 2018, 132, 4058-4058.	1.4	1
13	Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML). Blood, 2018, 132, 3895-3895.	1.4	0
14	Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cellâ€“dependent cytotoxicity. Blood, 2017, 129, 2246-2256.	1.4	23
15	Inhibition of USP10 induces degradation of oncogenic FLT3. Nature Chemical Biology, 2017, 13, 1207-1215.	8.0	89
16	Interleukin 21 â€“ its potential role in the therapy of B-cell lymphomas. Leukemia and Lymphoma, 2017, 58, 17-29.	1.3	20
17	A Functional Approach to Precision Medicine Identifies Targeted Therapies for Acute Myeloid Leukemia. Blood, 2017, 130, 853-853.	1.4	0
18	miR-181a negatively regulates NF-ÎºB signaling and affects activated B-cellâ€“like diffuse large B-cell lymphoma pathogenesis. Blood, 2016, 127, 2856-2866.	1.4	37

#	Article	IF	Citations
19	Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood, 2016, 128, 239-248.	1.4	17
20	Abstract 418: Mitochondrial perturbations as a novel approach to personalized medicine. , 2016, , .		0
21	FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML). Blood, 2016, 128, 1681-1681.	1.4	0
22	Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma. Blood, 2016, 128, 3969-3969.	1.4	0
23	Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood, 2015, 126, 1555-1564.	1.4	31
24	Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors. Leukemia, 2015, 29, 1587-1599.	7.2	17
25	Interleukin-21 Potently Induces Direct and Indirect Cytotoxicity of Mantle Cell Lymphoma. Blood, 2014, 124, 1776-1776.	1.4	1
26	Mirna-181a expression Lead to Longer Animal Survival and Slower Tumor-Growth Rate in Diffuse Large B-Cell Lymphoma Xenograft Models. Blood, 2014, 124, 2963-2963.	1.4	0
27	Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. Journal of Clinical Investigation, 2013, 123, 2616-2628.	8.2	59
28	CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood, 2013, 122, 1233-1242.	1.4	82
29	Targeting B-Cell Malignancies With Anti-CD20-Interleukin-21 Fusokine. Blood, 2013, 122, 377-377.	1.4	3
30	Abstract LB-328: Preclinical activity of interleukin 21 in mantle cell lymphoma.. , 2013, , .		0
31	B Cell Receptors Of Chlamydophila Psittaci negative MALT Lymphomas Of The Ocular Adnexa Recognize Common Self-Antigens. Blood, 2013, 122, 4266-4266.	1.4	0
32	Germinal Center Kinase Regulates The Proliferation and Survival Of Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 643-643.	1.4	0
33	Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. Blood, 2012, 119, 5478-5491.	1.4	39
34	miR-155 regulates HGAL expression and increases lymphoma cell motility. Blood, 2012, 119, 513-520.	1.4	74
35	Preclinical Activity of Brentuximab Vedotin (SGN-35) in Primary Effusion Lymphoma (PEL),. Blood, 2011, 118, 3728-3728.	1.4	2
36	Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach. Blood, 2011, 118, 438-438.	1.4	0

#	Article	IF	Citations
37	Synergistic Preclinical Activity of Bortezomib with Suberoylanilide Hydroxamic Acid (SAHA) in Primary Effusion Lymphoma (PEL). Blood, 2011, 118, 1650-1650.	1.4	0
38	Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13069-13074.	7.1	79